Yu L, et al. - Researchers used several computerized databases to find relevant studies published from inception to December 1, 2017 to assess the role of cancer susceptibility candidate 2 (CASC2) in multiple carcinomas. They calculated pooled HR with 95% CI to summarize the effect. They also used data from The Cancer Genome Atlas (TCGA) project, OncoLnc, TANRIC and lncRNAtor database. Through this meta-analysis and bioinformatics, they found that lower expression of CASC2 is associated with poorer prognosis of cancers, as well as a negative correlation with advanced tumor node metastasis (TNM), lymph node metastasis (LNM) and T stage. The association of higher expression of CASC2 with longer overall survival in patients with malignant tumors was revealed in the bioinformatics analysis.